We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray Brands Strengthens Domestic Lead With Strong Q1 Cannabis Growth
Read MoreHide Full Article
Key Takeaways
TLRY's Canadian cannabis revenues rose 4% to $51M in fiscal Q1 2026.
Tilray Brands expanded share in adult-use, gaining top ranks in pre-rolls, beverages, oils and edibles.
TLRY currently ranks #1 in flower and maintains a top-10 rank across all product categories.
Tilray Brands (TLRY - Free Report) delivered a strong quarter in Canada, reinforcing its position as the largest legal cannabis company in the country in terms of revenues. In the fiscal first quarter of 2026, Canadian cannabis revenues rose 4% year over year to $51 million, supported by the company’s significant scale, which includes approximately 5 million square feet of cultivation space and 210 metric tons of cannabis in production. This capacity positions TLRY to meet future domestic demand while also supplying international markets as regulations evolve.
In the adult-use channel, Tilray ranked among the top five licensed producers and continued to gain momentum, increasing market share and narrowing the gap to the #1 LP by 53 basis points. The company held the leading position in several key categories, including pre-rolls, beverages, oils, and chocolate edibles, and by the end of the quarter had also secured the #1 ranking in flower. Across the broader product landscape, Tilray consistently ranked among the top 10 in every category.
Looking ahead, the company anticipates long-term upside driven by still-low household cannabis penetration and potential regulatory improvements, including updates to excise taxes, expanded on-premise THC beverage consumption, and broader medical cannabis distribution through pharmacies.
Peer Update
Domestically, Cresco Labs (CRLBF - Free Report) delivered steady operational results for the third quarter, driven by strong wholesale momentum and expanded cultivation capacity. The company continued to hold leading share positions in key limited-license states, including the #1 retail share in Illinois and Ohio and the #1 branded wholesale share in Illinois, Pennsylvania and Massachusetts.
However, despite these operational strengths, the company's U.S. business remains highly exposed to the broader challenges of a tightly regulated and increasingly price-compressed domestic cannabis market. Revenues in the third quarter declined year over year, reflecting persistent top-line pressure.
Domestically, Canopy Growth (CGC - Free Report) reported solid momentum in its Canadian business during the fiscal second quarter, with meaningful improvement across both the adult-use and medical cannabis segments. The company saw notable progress in adult-use sales, supported by stronger commercial execution and the successful rollout of infused pre-rolls and all-in-one vape formats under flagship brands such as Tweed and 7ACRES. Canopy’s medical segment also continued to expand, benefiting from a growing insured patient base and higher-value product offerings. Additionally, ongoing cost-discipline measures contributed to improved operational efficiency and supported progress toward a more sustainable financial foundation.
TLRY’s Price Performance
In the past six months, Tilray Brands’ shares have gained 129.1%, outperforming the industry’s 1.8% growth. The S&P 500 composite has grown 18.6% in the same period.
Image Source: Zacks Investment Research
Discounted Valuation
TLRY currently trades at a forward 12-month Price-to-Sales (P/S) of 1.30X compared with the industry average of 3.16X.
Image Source: Zacks Investment Research
TLRY Stock Estimate Trend
Over the past 30 days, its loss per share estimate for 2025 has remained unchanged at 5 cents.
Image: Bigstock
Tilray Brands Strengthens Domestic Lead With Strong Q1 Cannabis Growth
Key Takeaways
Tilray Brands (TLRY - Free Report) delivered a strong quarter in Canada, reinforcing its position as the largest legal cannabis company in the country in terms of revenues. In the fiscal first quarter of 2026, Canadian cannabis revenues rose 4% year over year to $51 million, supported by the company’s significant scale, which includes approximately 5 million square feet of cultivation space and 210 metric tons of cannabis in production. This capacity positions TLRY to meet future domestic demand while also supplying international markets as regulations evolve.
In the adult-use channel, Tilray ranked among the top five licensed producers and continued to gain momentum, increasing market share and narrowing the gap to the #1 LP by 53 basis points. The company held the leading position in several key categories, including pre-rolls, beverages, oils, and chocolate edibles, and by the end of the quarter had also secured the #1 ranking in flower. Across the broader product landscape, Tilray consistently ranked among the top 10 in every category.
Looking ahead, the company anticipates long-term upside driven by still-low household cannabis penetration and potential regulatory improvements, including updates to excise taxes, expanded on-premise THC beverage consumption, and broader medical cannabis distribution through pharmacies.
Peer Update
Domestically, Cresco Labs (CRLBF - Free Report) delivered steady operational results for the third quarter, driven by strong wholesale momentum and expanded cultivation capacity. The company continued to hold leading share positions in key limited-license states, including the #1 retail share in Illinois and Ohio and the #1 branded wholesale share in Illinois, Pennsylvania and Massachusetts.
However, despite these operational strengths, the company's U.S. business remains highly exposed to the broader challenges of a tightly regulated and increasingly price-compressed domestic cannabis market. Revenues in the third quarter declined year over year, reflecting persistent top-line pressure.
Domestically, Canopy Growth (CGC - Free Report) reported solid momentum in its Canadian business during the fiscal second quarter, with meaningful improvement across both the adult-use and medical cannabis segments. The company saw notable progress in adult-use sales, supported by stronger commercial execution and the successful rollout of infused pre-rolls and all-in-one vape formats under flagship brands such as Tweed and 7ACRES. Canopy’s medical segment also continued to expand, benefiting from a growing insured patient base and higher-value product offerings. Additionally, ongoing cost-discipline measures contributed to improved operational efficiency and supported progress toward a more sustainable financial foundation.
TLRY’s Price Performance
In the past six months, Tilray Brands’ shares have gained 129.1%, outperforming the industry’s 1.8% growth. The S&P 500 composite has grown 18.6% in the same period.
Image Source: Zacks Investment Research
Discounted Valuation
TLRY currently trades at a forward 12-month Price-to-Sales (P/S) of 1.30X compared with the industry average of 3.16X.
Image Source: Zacks Investment Research
TLRY Stock Estimate Trend
Over the past 30 days, its loss per share estimate for 2025 has remained unchanged at 5 cents.
Image Source: Zacks Investment Research
TLRY stock currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.